Singapore Therapeutics Development Review (STDR) 2026 (Jul)
The STDR 2026 (Jul) grant from the Agency for Science Technology and Research supports advanced translational research and commercialization in therapeutics and biotech across diverse modalities in Singapore.
Funder: Agency for Science Technology and Research
Due Dates: August 27, 2026: Pre-Pilot (Full Proposal) | August 27, 2026: Pilot (Pitch Deck & Short Write-up)
Funding Amounts: Pre-Pilot: Up to S$325,000 per project (1 year) | Pilot: Up to S$1,000,000 per project (2 years, split across two phases)
Summary: Supports Singapore-based drug development and biotech projects with phased funding, expert mentoring, and industry-focused training.
Key Information: Applications must be submitted via iGrants and endorsed by relevant institutional offices before the deadline.
Description
The Singapore Therapeutics Development Review (STDR) 2026 (Jul) grant, led by the Agency for Science Technology and Research (A*STAR) with key partners, is a national initiative to accelerate drug discovery and biotech innovation in Singapore. The program offers phased funding and intensive project management for promising therapeutic projects, ranging from early-stage proof-of-concept efforts to industry-ready platforms. Awardees gain access to expert mentoring, entrepreneurial guidance, and structured training, including bootcamps and industry networking, to support commercialization and translational research impact. The grant is open to a wide spectrum of therapeutic modalities and disease areas, with an emphasis on advancing projects toward commercial viability and strengthening Singapore’s life sciences ecosystem.
